Mizuho analyst, Irina Koffler maintained her Buy rating after Teva Pharma (NYSE: TEVA) effectively defended its generics business and eased ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE